Murine anti-CD3 monoclonal antibody induces potent cytolytic activity in both T and NK cell populations

https://doi.org/10.1016/0008-8749(89)90002-6Get rights and content

Abstract

Antibodies specific for the CD3 complex have the capacity to both stimulate and inhibit a variety of T cell functions. We show here that a monoclonal antibody to the ϵ chain of CD3 can induce efficient non-MHC-restricted cytolytic activity in murine lymphocytes with peak activity occurring after 48 hr of incubation. In a panel of targets, the anti-CD3-activated effectors lysed tumor cells but not normal lymphoblasts. Cytolysis was not dependent on the presence of the antibody in the cytolytic assay. Moderate to high cytolytic activity was elicited from lymph nodes, spleen, and thymus by anti-CD3 treatment in vitro, whereas only low activity was apparent in bone marrow. The precursors of anti-CD3-activated cells consisted largely of mature T cells, although a smaller component of immature T cells was also involved. Thus, separation of thymocytes based on adhesion to peanut agglutinin revealed that both positive (immature) and negative (mature) fractions could be activated, while cytotoxic pretreatment of spleen cells with an antibody (J11d) to immature T cells before anti-CD3 activation significantly decreased the resulting cytotoxicity. The majority of precursors in spleen were Thy 1+ and CD8+ and/or AGM1+. Antibody depletion studies showed that the effector cells have both a T and a NK component consisting of Thy 1+, CD5+, CD8+, CD4, and AGM1 cells and Thy 1, CD5, CD8, CD4, and AGM1+ cells, respectively. The production of significant amounts of IL-2 and TNF in culture following anti-CD3 treatment, along with the synergistic effect of exogenously added IL-2, suggests that one or both of the effector cell types could be induced by lymphokines. The intraperitoneal administration of the anti-CD3 antibody induces cytolytic activity in vivo. Therefore, the direct activation of cytolysis by anti-CD3 antibody and the additional effects, both direct and synergistic, of lymphokines produced by the activated lymphocytes could conceivably provide a potent anti-tumor therapy.

References (69)

  • L.E. Samelson et al.

    Cell

    (1985)
  • H.C. Oettgen et al.

    Hum. Immunol

    (1987)
  • H.C. Oettgen et al.

    Cell

    (1985)
  • D.A. Flick et al.

    J. Immunol. Methods

    (1984)
  • Y. Reisner et al.

    Cell. Immunol

    (1976)
  • M. Kriegler et al.

    Cell

    (1988)
  • W.G. Hauer et al.

    J. Exp. Med

    (1987)
  • P. Moingeon et al.

    Nature (London)

    (1987)
  • M.B. Brenner et al.

    Nature (London)

    (1987)
  • R. Van de Griend et al.

    J. Immunol

    (1988)
  • A. Weiss et al.

    J. Exp. Med

    (1984)
  • T. Saito et al.

    J. Immunol

    (1987)
  • S.C. Meuer et al.

    J. Exp. Med

    (1983)
  • J.B. Imboden et al.

    J. Immunol

    (1985)
  • L.E. Samelson et al.
  • A.E. Nel et al.

    J. Immunol

    (1987)
  • S. Cockroft et al.

    Immunology

    (1987)
  • L.E. Samelson et al.

    J. Immunol

    (1987)
  • S.C. Meuer et al.
  • O. Leo et al.
  • J.F. Leeuwenberg et al.

    J. Immunol

    (1985)
  • R.W. Sauerwein et al.

    Eur. J. Immunol

    (1988)
  • D.E. Martin et al.
  • E. Kedar et al.

    Clin. Immunol. Immunother

    (1982)
  • J.J. Mule et al.

    J. Immunol

    (1985)
  • Y.L. Matory et al.

    J. Biol. Response Modifiers

    (1985)
  • J.C. Winkelhake et al.

    Cancer Res

    (1987)
  • M. Iigo et al.

    Cancer Res

    (1988)
  • K. Naito et al.

    Cancer Res

    (1988)
  • M.Z. Papa et al.

    Cancer Res

    (1988)
  • R. Heicappell et al.

    J. Immunol

    (1987)
  • L.M. Muul et al.

    J. Immunol

    (1987)
  • J.J. Mule et al.

    J. Immunol

    (1987)
  • T. Chou et al.

    J. Immunol

    (1988)
  • Cited by (0)

    This work was supported by the National Cancer Institute of Canada.

    1

    J.S. is a fellow of the NCIC.

    2

    D.W.H. is a fellow of the Medical Research Council of Canada.

    3

    J.C.R. is a MRC scientist.

    View full text